Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Godaddy Inc (GDDY) Price & Performance

AbCellera Biologics IncTrade
Godaddy IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Godaddy Inc — how do they compare? AbCellera Biologics Inc trades at $9.95 (market cap $2.99B), while Godaddy Inc trades at $90.76 (market cap $11.49B). The key difference: Godaddy Inc is far larger — about 3.8× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.

ABCLGDDY
Market Cap
$2.99B$11.49B
Sector
HealthTechnology
52-Week High
$9.76$148.88
52-Week Low
$2.78$75.07
Enterprise Value
$2.58B$14.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Godaddy Inc

GoDaddy (GDDY) trades at $91.49, up 0.46% today, with a neutral technical signal and strong fundamentals including a 17.83% net income margin and consistent earnings beats. Revenue growth is steady, projected at $5.1B for 2026, while recent news highlights legal investigations into potential securities violations, creating investor uncertainty.

The stock offers value with a P/E of 13.48 and a consensus price target of $112.13, but risks include ongoing legal scrutiny and high debt levels. Analyst sentiment remains bullish with 57% buy ratings, though technical indicators suggest near-term consolidation around key support at $90.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Godaddy Inc

GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.

Read more on GDDY